Nanocarriers as an emerging platform for cancer therapy - PubMed (original) (raw)
Review
Nanocarriers as an emerging platform for cancer therapy
Dan Peer et al. Nat Nanotechnol. 2007 Dec.
Abstract
Nanotechnology has the potential to revolutionize cancer diagnosis and therapy. Advances in protein engineering and materials science have contributed to novel nanoscale targeting approaches that may bring new hope to cancer patients. Several therapeutic nanocarriers have been approved for clinical use. However, to date, there are only a few clinically approved nanocarriers that incorporate molecules to selectively bind and target cancer cells. This review examines some of the approved formulations and discusses the challenges in translating basic research to the clinic. We detail the arsenal of nanocarriers and molecules available for selective tumour targeting, and emphasize the challenges in cancer treatment.
Similar articles
- Nanotechnology platforms and physiological challenges for cancer therapeutics.
Kim KY. Kim KY. Nanomedicine. 2007 Jun;3(2):103-10. doi: 10.1016/j.nano.2006.12.002. Epub 2007 Apr 17. Nanomedicine. 2007. PMID: 17442621 Review. - Nanomedicine: nanocarriers shape up for long life.
Nishiyama N. Nishiyama N. Nat Nanotechnol. 2007 Apr;2(4):203-4. doi: 10.1038/nnano.2007.88. Nat Nanotechnol. 2007. PMID: 18654260 No abstract available. - Nanoparticle therapeutics: a personal perspective.
McNeil SE. McNeil SE. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2009 May-Jun;1(3):264-71. doi: 10.1002/wnan.6. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2009. PMID: 20049796 - Cell-targeting and cell-penetrating peptides for delivery of therapeutic and imaging agents.
Juliano RL, Alam R, Dixit V, Kang HM. Juliano RL, et al. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2009 May-Jun;1(3):324-35. doi: 10.1002/wnan.4. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2009. PMID: 20049800 Review. - Is nanotechnology ready for primetime?
Brower V. Brower V. J Natl Cancer Inst. 2006 Jan 4;98(1):9-11. doi: 10.1093/jnci/djj028. J Natl Cancer Inst. 2006. PMID: 16391365 No abstract available.
Cited by
- Polydopamine-based surface modification for the development of peritumorally activatable nanoparticles.
Gullotti E, Park J, Yeo Y. Gullotti E, et al. Pharm Res. 2013 Aug;30(8):1956-67. doi: 10.1007/s11095-013-1039-y. Epub 2013 Apr 23. Pharm Res. 2013. PMID: 23609560 Free PMC article. - Barriers to antibody therapy in solid tumors, and their solutions.
Matsumura Y. Matsumura Y. Cancer Sci. 2021 Aug;112(8):2939-2947. doi: 10.1111/cas.14983. Epub 2021 Jun 24. Cancer Sci. 2021. PMID: 34032331 Free PMC article. Review. - 5-Fluorouracil nanoparticles inhibit hepatocellular carcinoma via activation of the p53 pathway in the orthotopic transplant mouse model.
Cheng M, He B, Wan T, Zhu W, Han J, Zha B, Chen H, Yang F, Li Q, Wang W, Xu H, Ye T. Cheng M, et al. PLoS One. 2012;7(10):e47115. doi: 10.1371/journal.pone.0047115. Epub 2012 Oct 15. PLoS One. 2012. PMID: 23077553 Free PMC article. - Systemic delivery of SapC-DOPS has antiangiogenic and antitumor effects against glioblastoma.
Wojton J, Chu Z, Mathsyaraja H, Meisen WH, Denton N, Kwon CH, Chow LM, Palascak M, Franco R, Bourdeau T, Thornton S, Ostrowski MC, Kaur B, Qi X. Wojton J, et al. Mol Ther. 2013 Aug;21(8):1517-25. doi: 10.1038/mt.2013.114. Epub 2013 Jun 4. Mol Ther. 2013. PMID: 23732993 Free PMC article. - Nanoparticle shape improves delivery: rational coarse grain molecular dynamics (rCG-MD) of taxol in worm-like PEG-PCL micelles.
Loverde SM, Klein ML, Discher DE. Loverde SM, et al. Adv Mater. 2012 Jul 24;24(28):3823-30. doi: 10.1002/adma.201103192. Epub 2011 Nov 22. Adv Mater. 2012. PMID: 22105885 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources